C1q‐tumour necrosis factor‐related protein 8 (CTRP8) is a novel interaction partner of relaxin receptor RXFP1 in human brain cancer cells. Issue 4 (December 2013)

• Record Type: Journal Article
• Authors: Glogowska, Aleksandra; Kunanuvat, Usakorn; Stetefeld, Jörg; Patel, Trushar R; Thanasupawat, Thatchawan; Krcek, Jerry; Weber, Ekkehard; Wong, G William; Del Bigio, Marc R; Hoang‐Vu, Cuong; Hombach‐Klonisch, Sabine; Klonisch, Thomas
• Is Part Of: Journal of pathology. Volume 231:Issue 4(2013)
• Page Start: 466
• Page End: 479
• Publication Date: 2013-12
• Subjects: CTRP8 -- brain cancer -- RXFP1 -- relaxin receptor -- cathepsin; Pathology -- Periodicals; 616.07
• DOI: 10.1002/path.4257
• Languages: English
• ISSNs: 0022-3417

Abstract

Abstract: We report a novel ligand–receptor system composed of the leucine‐rich G‐protein‐coupled relaxin receptor, RXFP1, and the C1q‐tumour necrosis factor‐related protein 8 (CTRP8) in human primary brain cancer, a tumour entity devoid of the classical RXFP1 ligands, RLN1–3. In structural homology studies and computational docking experiments we delineated the N‐terminal region of the globular C1q region of CTRP8 and the leucine‐rich repeat units 7 and 8 of RXFP1 to mediate this new ligand–receptor interaction. CTRP8 secreted from HEK293T cells, recombinant human (rh) CTRP8, and short synthetic peptides derived from the C1q globular domain of human CTRP8 caused the activation of RXFP1 as determined by elevated intracellular cAMP levels and the induction of a marked pro‐migratory phenotype in established glioblastoma (GB) cell lines and primary cells from GB patients. Employing a small competitor peptide, we were able to disrupt the CTRP8–RXFP1‐induced increased GB motility. The CTRP8–RXFP1‐mediated migration in GB cells involves the activation of PI3K and specific protein kinase C pathways and the increased production/secretion of the potent lysosomal protease cathepsin B (cathB), a known prognostic marker of GB. Specific inhibition of CTRP8‐induced cathB activity effectively blocked the ability of primary GB to invade laminin matrices. Finally, co‐immunoprecipitation studies revealed the direct interaction of human CTRP8 with RXFP1. Our results support a therapeutic approach in GB aimed at targeting multiple steps of the CTRP8–RXFP1 signalling pathway by a combined inhibitor and peptide‐based strategy to block GB dissemination within the brain. Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.